Related references
Note: Only part of the references are listed.Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: A multi-institutional retrospective study
Yasuhiro Nakamura et al.
JOURNAL OF DERMATOLOGY (2017)
Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer
Sanja Stevanovic et al.
SCIENCE (2017)
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Dung T. Le et al.
SCIENCE (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Viktoria Bergqvist et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott J. Antonia et al.
LANCET ONCOLOGY (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The head and neck cancer immune landscape and its immunotherapeutic implications
Rajarsi Mandal et al.
JCI INSIGHT (2016)
Small cell neuroendocrine carcinoma of larynx: case series and literature review
Muhammad Shahid Iqbal et al.
JOURNAL OF LARYNGOLOGY AND OTOLOGY (2015)
Comprehensive genomic profiles of small cell lung cancer
Julie George et al.
NATURE (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
Martina Sanlorenzo et al.
JAMA DERMATOLOGY (2015)
Prognostic Significance of Cutaneous Adverse Events Associated With Pembrolizumab Therapy
Jennifer A. Lo et al.
JAMA ONCOLOGY (2015)
Human Papillomavirus and Overall Survival After Progression of Oropharyngeal Squamous Cell Carcinoma
Carole Fakhry et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Immunologic and metabolic characteristics of HPV-negative and HPV-positive head and neck squamous cell carcinomas are strikingly different
Rosemarie Krupar et al.
VIRCHOWS ARCHIV (2014)
Small Cell Neuroendocrine Carcinoma of the Oropharynx Harbouring Oncogenic HPV-Infection
Timothy Bates et al.
HEAD & NECK PATHOLOGY (2014)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
HPV-associated Neuroendocrine Carcinoma of the Oropharynx: A Rare New Entity With Potentially Aggressive Clinical Behavior
Stefan Kraft et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
Human Papillomavirus-Related Small Cell Carcinoma of the Oropharynx
Justin A. Bishop et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2011)
Should Extrapulmonary Small Cell Cancer Be Managed Like Small Cell Lung Cancer?
Sinead M. Brennan et al.
CANCER (2010)
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
K. Kian Ang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Human Papillomavirus in Head and Neck Cancer: Its Role in Pathogenesis and Clinical Implications
Christine H. Chung et al.
CLINICAL CANCER RESEARCH (2009)
SMALL CELL CARCINOMA OF THE HEAD AND NECK: THE UNIVERSITY OF MIAMI EXPERIENCE
Georges F. Hatoum et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2009)
Share Paper
